CEL-SCI Co. (CVM) Short Interest Update

CEL-SCI Co. (NYSEAMERICAN:CVM) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 2,408,016 shares, an increase of 23.0% from the April 15th total of 1,957,060 shares. Based on an average daily volume of 755,948 shares, the short-interest ratio is presently 3.2 days. Currently, 7.7% of the company’s stock are sold short.

Shares of CVM opened at $5.02 on Wednesday. CEL-SCI has a 12 month low of $0.82 and a 12 month high of $8.47.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. increased its position in shares of CEL-SCI by 6.4% in the 1st quarter. Advisor Group Inc. now owns 33,378 shares of the company’s stock valued at $118,000 after acquiring an additional 2,000 shares during the period. Thoroughbred Financial Services LLC increased its position in shares of CEL-SCI by 21.1% in the 1st quarter. Thoroughbred Financial Services LLC now owns 13,921 shares of the company’s stock valued at $49,000 after acquiring an additional 2,428 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in shares of CEL-SCI in the 1st quarter valued at $42,000. Bank of New York Mellon Corp acquired a new position in shares of CEL-SCI in the 4th quarter valued at $38,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of CEL-SCI in the 1st quarter valued at $56,000.

WARNING: This story was first posted by WKRB News and is the property of of WKRB News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.wkrb13.com/2019/05/22/cel-sci-co-cvm-short-interest-update-2.html.

CEL-SCI Company Profile

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Further Reading: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.